Mayinglong Pharmaceutical Group Company Overview

  • Year Founded
  • 1994

Year Founded

  • Status
  • Public

  • Employees
  • 2,544

Employees

  • Stock Symbol
  • 600993

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $3.95
  • (As of Friday Closing)

Mayinglong Pharmaceutical Group Company General Information

Description

Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Number 100 Zhoujiawan
  • Nanhu Lake Wuchang District
  • Wuhan, Hubei 430064
  • China
+86 027
Primary Industry
Pharmaceuticals
Stock Exchange
SHG
Corporate Office
  • Number 100 Zhoujiawan
  • Nanhu Lake Wuchang District
  • Wuhan, Hubei 430064
  • China
+86 027

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mayinglong Pharmaceutical Group Company Stock Performance

As of 20-Nov-2026, Mayinglong Pharmaceutical Group Company’s stock price is $3.95. Its current market cap is $1.7B with 431M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.95 $3.96 $3.12 - $4.29 $1.7B 431M 5.52M $0.20

Mayinglong Pharmaceutical Group Company Financials Summary

As of 30-Sep-2026, Mayinglong Pharmaceutical Group Company has a trailing 12-month revenue of $579M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,111,328 1,380,023 1,180,241 1,164,569
Revenue 578,920 537,677 519,552 443,364
EBITDA 103,617 107,121 94,867 79,314
Net Income 86,299 80,860 73,597 62,651
Total Assets 842,441 776,972 709,845 681,309
Total Debt 10,635 14,168 32,084 38,413
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mayinglong Pharmaceutical Group Company Patents

Mayinglong Pharmaceutical Group Company Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026119097-A1 External-use traditional chinese medicine composition for treating anorectal diseases, traditional chinese medicine formulation, preparation method therefor, and use thereof Pending 02-Dec-2024
US-20260139220-A1 Lacticaseibacillus rhamnosus mbp01 and combination thereof for preventing and treating irritable bowel syndrome Pending 15-Nov-2024
WO-2026103131-A1 Lactobacillus rhamnosus mbp01 for preventing and treating irritable bowel syndrome and composition thereof Pending 15-Nov-2024
WO-2026061469-A1 Heteroaromatic amine compound, pharmaceutical composition thereof and use thereof Pending 19-Sep-2024
US-20140087010-A1 Preparation method for extractive of jinxuan hemorrhoid washing powder botanicals Active 08-Mar-2011 A61K36/538
To view Mayinglong Pharmaceutical Group Company’s complete patent history, request access »

Mayinglong Pharmaceutical Group Company Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mayinglong Pharmaceutical Group Company Investments (8)

Mayinglong Pharmaceutical Group Company’s most recent deal was a Secondary Transaction - Private with Mayinglong Changqing Hospital. The deal was made on 20-Oct-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Mayinglong Changqing Hospital 20-Oct-2022 Secondary Transaction - Private Hospitals/Inpatient Services
Health Medicare 01-Sep-2020 Corporate Pharmaceuticals
Okay Pharmaceutical 23-Dec-2016 Corporate Specialty Chemicals
Jilang Biotechnology 25-Feb-2016 Early Stage VC Diagnostic Equipment
Leimai Technology 25-May-2015 Later Stage VC Therapeutic Devices
You’re viewing 5 of 8 investments. Get the full list »

Mayinglong Pharmaceutical Group Company ESG

Risk Overview

Risk Rating

Updated December, 31, 2023

30.88 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Pharmaceuticals

Subindustry

of 435

Rank

Percentile

To view Mayinglong Pharmaceutical Group Company’s complete esg history, request access »

Mayinglong Pharmaceutical Group Company Exits (1)

Mayinglong Pharmaceutical Group Company’s most recent exit was on 28-Jan-2000 from Dafu Pharmaceutical. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Dafu Pharmaceutical 28-Jan-2000 Completed
To view Mayinglong Pharmaceutical Group Company’s complete exits history, request access »

Mayinglong Pharmaceutical Group Company Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Mayinglong Changqing Hospital Beijing, China 2009

Mayinglong Pharmaceutical Group Company FAQs

  • When was Mayinglong Pharmaceutical Group Company founded?

    Mayinglong Pharmaceutical Group Company was founded in 1994.

  • Where is Mayinglong Pharmaceutical Group Company headquartered?

    Mayinglong Pharmaceutical Group Company is headquartered in Wuhan, China.

  • What is the size of Mayinglong Pharmaceutical Group Company?

    Mayinglong Pharmaceutical Group Company has 2,544 total employees.

  • What industry is Mayinglong Pharmaceutical Group Company in?

    Mayinglong Pharmaceutical Group Company’s primary industry is Pharmaceuticals.

  • Is Mayinglong Pharmaceutical Group Company a private or public company?

    Mayinglong Pharmaceutical Group Company is a Public company.

  • What is Mayinglong Pharmaceutical Group Company’s stock symbol?

    The ticker symbol for Mayinglong Pharmaceutical Group Company is 600993.

  • What is the current stock price of Mayinglong Pharmaceutical Group Company?

    As of 20-Nov-2026 the stock price of Mayinglong Pharmaceutical Group Company is $3.95.

  • What is the current market cap of Mayinglong Pharmaceutical Group Company?

    The current market capitalization of Mayinglong Pharmaceutical Group Company is $1.7B.

  • What is Mayinglong Pharmaceutical Group Company’s current revenue?

    The trailing twelve month revenue for Mayinglong Pharmaceutical Group Company is $579M.

  • What is Mayinglong Pharmaceutical Group Company’s annual earnings per share (EPS)?

    Mayinglong Pharmaceutical Group Company’s EPS for 12 months was $0.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process